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wMeningitis Research Foundation, Bristol, UKThe authors regret the following footnote should have been included with Table 6:
In cases where Chloramphenicol is used (known anaphylaxis to penicillins or cephalosporins) the dose may be reduced to
12.5 mg/kg 6 hourly if the patient is recovering, to reduce the risk of a dose-related anaemia.
Table 6 is reproduced again here with the addition of the footnote.
The authors would like to apologise for any inconvenience caused.Table 6 Definitive antibiotic treatment.
Aetiology Antibiotic (s) Dose Alternative antibiotic
choices
Dose Durationb
Neisseria meningitidis Cefotaxime
OR
Ceftriaxone
2 g 6 hourly/2 g
12 hourly
Chloramphenicol
(if anaphylaxis) OR
Benzylpenicillin
25 mg/kg
6 hourly
2.4 g 4 hourly
5 days
Streptococcus pneumoniae
(sensitivities unknown or
penicillin resistant,
cephalosporin sensitive)
Cefotaximea
OR
Ceftriaxonea
2 g 6 hourly
2 g 12 hourly
Chloramphenicol 25 mg/kg
6 hourly
10 days (if stable)
Up to 14 days
if taking longer
to respond
Streptococcus pneumoniae
(penicillin sensitive, MIC 0.06)
Benzylpenicillin
OR
Cefotaxime
OR
Ceftriaxonec
2.4 g 4 hourly
2 g 6 hourly/2 g
12 hourly
Chloramphenicol 25 mg/kg
6 hourly
10 days (if stable)
Up to 14 days
if taking longer
to respond
Streptococcus pneumoniae
(penicillin and cephalosporin
non-susceptible, penicillin
MIC> 0.06 or cefotaxime/
ceftriaxone MIC> 0.5)
Cefotaxime
OR
Ceftriaxone
AND
Vancomycind
OR
Rifampicin
2 g 6 hourly
2 g 12 hourly
15e20 mg/kg
12 hourly
(adjusting
according to
serum trough
levels)
600 mg bd
Chloramphenicole 25 mg/kg
6 hourly
14 days
Listeria monocytogenes Amoxicillin 2 g 4 hourly Co-trimoxazole 10e20 mg/kg
(of the
trimethoprim
component)
in 4 divided
doses
21 days
Haemophilus influenzae Cefotaxime
OR
Ceftriaxone
2 g 6 hourly
2 g 12 hourly
Moxifloxacin 400 mg od 10 days
a Add in IV Vancomycin 15e20 mg/kg bd or Rifampicin 600 mg bd if penicillin resistance is suspected e.g. patient has recently arrived
from a country where penicillin resistant pneumococci is prevalent (if unsure, check with local infectious diseases/microbiology
expertise.
b Treatment durations may need to be extended if patient is not responding.
c If low risk of Clostridium difficile infection and/or requiring outpatient therapy.
d Serum vancomycin trough concentrations of 15e20 ug/ml should be aimed for.
e In cases where Chloramphenicol is used (known anaphylaxis to penicillins or cephalosporins) the dose may be reduced to 12.5 mg/kg
6 hourly if the patient is recovering, to reduce the risk of a dose-related anaemia.
